XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Interventions: Drug: XELOX combined with Fruquintinib and Sintilimab Sponsors: Xiaofeng Chen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials